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Introduction 
Pulmonary involvement in scleroderma commonly presents 
as diffuse, progressive fibrosis (1,2). 
Rarely, chest wall skin infiltration can manifest in a 
restrictive pattern with Type II (hypercapnic) respiratory 
failure (3). This can often prove difficult to manage. 
Here, we present a case of severe sclerodermic chest wall 
restriction which was significantly improved by nocturnal 
intermittent non-invasive positive pressure ventilation 
(NIPPV). 
Case Report 
A 37-year-old man of Jamaican origin with 15 years’ 
history of diffuse cutaneous systemic sclerosis was referred 
for assessment of possible pulmonary involvement. 
On presentation 10 years previously, the patient had no 
respiratory symptoms. His exercise tolerance was normal 
and he was a life-long non-smoker. 
He was thin, with marked scleroderma involving the 
face, shoulders, trunk and hands. He had severe sclero- 
dactyly and calcinosis of the fingers, but was not clubbed 
or cyanosed. There was prominent wasting of the chest 
muscles. Chest movements were limited to an expansion 
of 2 cm due to severe sclerodermic infiltration of the chest 
wall skin. There were no findings to suggest interstitial 
lung disease and the rest of the physical examination was 
unremarkable. 
Chest radiography showed a narrow AP diameter, 
but was otherwise normal with no evidence of fibrosis. 
Thin section computed tomography (CT) scans of the 
chest revealed decreased lung volumes with a uniform 
appearance of crowding of bronchovascular bundles 
throughout both lung fields. There was minor evidence of 
bilateral apical scarring, but no suggestion of fibrosing 
alveolitis. 
His pulmonary function tests reflected a severe restrictive 
ventilatory defect with a reduced gas transfer (7X0) but a 
high/normal gas transfer index (KCO) (Table 1). Fibre- 
optic bronchoscopy, broncheoalveolar lavage and trans- 
bronchial biopsy were normal. Chest wall compliance at 
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that stage was markedly reduced at 0.062 1 cm- ‘ H,O 
(normal range 0.1-0.2 1 cm- ’ H,O). 
The clinical, radiological and physiological features were 
all consistent with extrinsic thoracic restriction due to 
marked sclerodermic skin infiltration. 
The patient was kept under regular review and 4 years 
following the original referral he reported increasing 
breathlessness on exertion. The chest radiographs remained 
unchanged but there was a significant deterioration in both 
lung volumes and gas transfer (nC0). The KC0 remained 
normal (Table 1). 
There was no evidence of intrinsic lung disease, but 
chest wall expansion was severely restricted as a result of 
worsening sclerodermic infiltration. Due to the deteriora- 
tion in lung function a trial of high-dose oral corticosteroids 
(prednisolone 60 mg day-‘) were commenced in an 
attempt to improve his skin disease. These were gradually 
reduced to a maintenance dose of 10 mg day - I. 
After 1 month the patient reported that his skin felt 
slightly looser, but no significant improvement in respirat- 
ory function was noted with continued steroid treatment. 
Within 1 year his respiratory function had worsened. 
Serial arterial blood gases reflected increasing hypoventi- 
lation, such that by July 1992 the PaCo, had reached a 
peak of 8.8 kPa (Table 2). Obstructive sleep apnoea was 
excluded on polysomnography. 
At this stage, he was admitted for an intensive course of 
nasal positive pressure ventilation and was discharged from 
hospital 10 days later on a domiciliary nocturnal nasal 
ventilator. Within 4 weeks, the patient began to notice a 
marked improvement in respiratory function. Thirteen 
months from the onset of treatment with NIPPV there was 
a considerable clinical and physiological improvement, 
reflected in both lung volumes and arterial blood gases 
(Tables 1 and 2, respectively). 
The patient continues on domiciliary nocturnal NIPPV 
treatment. His exercise tolerance is now unlimited on the 
flat and his respiratory function, in terms of both volumes 
and gas exchange, is maintained. His scleroderma, although 
still severe, remains stable. 
Discussion 
Non-invasive ventilation has long had an established role 
in various forms of chronic and acute respiratory disease 
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TABLE 1. Pulmonary function tests (i) at presentation (March 1986); (ii) on development of 
respiratory symptoms (September 1990); (iii) b e ore f commencement of NIPPV (August 1992); (iv) 
following 13 months of intermittent non-invasive ventilation (October 1993) 
(Predicted values) 
0) (ii) (iii) (iv) 
1986 1990 1992 1993 
FEV, ml (27104410) 1780 1190 1020 1310 
FVC ml (3360-5360 1800 1220 1030 1320 
FEVJFVC (67-90) % 99 97 99 99 
TLC ml (5030-6810) 3770 3300 3340 3360 
VA ml (4680-6330) 3080 2630 2100 2480 
TLC0 SI (8.39-11.35) 6.36 4.89 4.23 4.34 
KC0 SI (1.45-1.96) 2.06 1.89 2.01 1.75 
TABLE 2. Arterial blood gases 
PaO, PaCO, HCO, BET Sats 
PH kPa kPa mm01 I ~ ’ mmoll-’ % 
1992 
Unassisted ventilation before 
referral for NIPPV* (on air) 
On NIPPV 
(1 1 entrained 0,) 
1993 
Unassisted ventilation after 13 
months of domiciliary NIPPV 
7.37 8.12 8.80 38.10 IO.30 90 
7.46 16.7 6.60 35.40 11.50 99 
7.40 11.71 6.91 31.40 5.60 96 
“Nasal non-invasive positive pressure ventilation 
I-Base excess. 
(4:5). The success of NIPPV in our patient has been quite 
dramatic, with a striking improvement in respiratory 
function. 
The mechanism by which sclerodermic chest wall disease 
leads to hypercapnic respiratory failure and the relief 
provided by non-invasive intermittent ventilation probably 
involves several factors. 
It has been suggested that respiratory muscles can 
become ‘fatigued’ in association with chronic respiratory 
failure (6,7). This inability of respiratory muscles to sustain 
tension can also develop with ventilatory stresses such 
as increased respiratory resistance due to sclerodermic 
chest wall infiltration. By resting the diaphragm and other 
respiratory muscles, non-invasive ventilation can lead to a 
restoration of function and hence an improvement in both 
gas exchange and symptoms (8-10). 
Secondly, it is possible that intermittent ventilation 
increases chest wall compliance (6). Hence, stretching the 
respiratory muscles and overlying skin may improve 
respiratory function by increasing vital capacity, regardless 
of muscle strength. Our patient required a relatively high 
inflation pressure of 30 cmH,O, which probably reflects 
his reduced chest wall compliance. However, it is worth 
noting that these pressures are measured at the mask and 
are not necessarily the pressures seen by the lungs, consid- 
ering the often significant pressure drop across the upper 
airways. 
A third factor is the gradual down-regulation in central 
respiratory sensitivity as a consequence of chronically 
raised levels of CO,. Intermittent ventilatory support (in 
our case, over a variable nocturnal period) would allow the 
re-setting of CO, sensitivity and avoidance or relief of this 
so called ‘central fatigue’ phenomenon (6,7). 
In conclusion, we have presented a case of a man with 
severe sclerodermic chest wall involvement, resulting in 
progressive extrinsic and hypercapnic respiratory failure. 
The patient was unusual in that he had no evidence of 
interstitial pulmonary fibrosis; which is the more common 
pulmonary presentation in scleroderma. 
A trial of high-dose oral steroids failed to alter the 
continuing deterioration in respiratory function. How- 
ever, treatment with domiciliary nocturnal non-invasive 
ventilation resulted in significant clinical improvement with 
reversal of his hypercapnic respiratory failure. 
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Plewropulmonary disease as a side-effect of 
treatment with bromcriptine 
R. COMET”, C. DOMINGO”, J. J. SUCH”, G. RIBERA+, J. SANS” AND A. MAR~N” 
“S. Pneumologia, ‘S. Neurologia, Consorci Hospitalavi de1 Pave Tat&, Barcelona, Spain 
Introduction 
Bromocriptine is a dopamine agonist frequently used to 
treat Parkinson’s disease, either in association with, or as 
an alternative to, classical dopamine agonists. The main 
side-effects of bromocriptine are fairly well recognized. 
Although the association of pleuropulmonary disorders 
has not been convincingly proved, accumulating evidence 
suggests a cause-and-effect relationship. Pleuropulmonary 
involvement can present as pleural thickening, pleural 
effusion and interstitial shadowings. 
We report a patient who developed pleuropulmonary 
disease after long-term use of bromocriptine (1,2). 
Case Report 
A 63-year-old Caucasian non-smoking female with a past 
clinical history of hypertension, colon diverticulosis and no 
relevant occupational history, was diagnosed as having 
Parkinson’s disease in 1988. After temporary treatment 
with L-Dopa, in 1990 the therapy was changed to bromo- 
criptine. In July 1994 the patient was referred to our 
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hospital for a 6 months’ history of progressive dyspnoea, 
anorexia and a weight of lost of 10 kg. Physical examina- 
tion disclosed only the presence of crackles at both lung 
bases. Blood analysis: Erythrocyte sedimentation rate 
(ESR), 106; leukocyte count, haemoglobin and biochemis- 
try data were normal; LDH 356 U l- ‘; proteins 81 g l- ‘; 
Latex and Waler-Rose, Carcino-embrionary antigen, 
Alpha-fetoprotein and a screening of auto-antibodies were 
negative. C-reactive protein (CRP): 9.26. Angiotensin con- 
verting enzyme value was within normal limits. Arterial 
blood gases breathing room air: PaO, 83; PaCO, 40; 
pH 7.44. PPD test was negative. Chest X-ray showed a 
bilateral pleural effusion and bilateral interstitial shadow- 
ings [Plate l(a)]. A thoracocentesis disclosed the presence of 
a sero-hematic pleural effusion with: 390 red blood cells 
mmp3; 10 leukocytes mm - 3; proteins 25 g 1 - i; LDH 
125 U I- ‘; ADA 3.7 U 1~ ‘. The cytological examination 
and the Lowenstein culture was negative. Bronchoscopy 
was normal. The bronchoalveolar lavage showed: 740 cells 
mmp3; macrophages 8 1%; lymphocytes 1%; polymorpho- 
nuclears, 1%; no malignant cells or asbestos fibres were 
observed in the bronchoaspirate. A pleural biopsy was 
performed revealing the presence of chronic fibrinous 
pleuritis. A thoracic computed tomography (CT) scan evi- 
denced a bilateral pleural effusion and fibrotic and ground 
glass images in both lower lungs. Forced spirometry: FEV, 
1.120 1 (60%); FVC 1.3201 (52%); FEV,/FVC 85%. 
RV 1.231 1 (71%); TLC 2.98 1 (68%). Co-transfer was nor- 
mal. During the patient’s in-hospital stay, bromocriptine 
